• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home StudyGraphics

#VisualAbstract: Novel SARS-CoV-2 vaccine (ChAdOx1 nCoV-2) offers promising safety and immunogenicity

byConstance Wu
August 4, 2020
in StudyGraphics
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. The novel SARS-CoV-2 vaccine, ChAdOx1 nCoV-2, offered a reasonable safety profile with no serious adverse events in first phase 1/2 trial.

2. ChAdOx1 nCoV-2 showed neutralizing antibody responses against SARS-CoV-2 in the majority of patients.

Evidence Rating Level: 1 (Excellent)

Study Rundown: No vaccines have been approved for the prevention of COVID-19 to date. Replication-deficient viral vectored ChadOx1 vaccines have shown good safety and immunogenic profiles in immunocompromised and elderly individuals, respectively, and stand as a promising candidate for a SARS-CoV-2 vaccine. This phase 1/2 single-blind, randomized controlled trial tested the safety and immunogenicity of the novel ChAdOx1 nCoV-2 vaccine, a replication-deficient simian adenovirus-based vaccine which has previously shown efficacy in rhesus macaques, in a sample of healthy adults. Overall, ChAdOx1 nCoV-2 showed more adverse events than the comparator vaccine, MenACWY; however, there were no serious adverse events in the ChAdOx1 nCoV-2 arm, and administration of prophylactic paracetamol significantly reduced most adverse events. Antibodies against SARS-CoV-2 spike protein increased in the ChAdOx1 nCoV-2 arm by 28 days, and all those exposed to SARS-CoV-2 exhibited neutralizing antibody responses. Important limitations of this study include the relatively short follow-up, single-blinded design, and limited generalizability; most participants were young, healthy and Caucasian. However, given the promising safety, tolerability and immunogenicity profiles of the ChAdOx1 nCoV-2 vaccine, testing for efficacy and safety in older adults and the development of phase 2 and 3 trials are certainly merited.

Click to read the study in The Lancet

In-Depth [randomized controlled trial]: This two-arm, phase 1/2, participant-blinded, multicenter, randomized controlled trial was conducted in five centers across the United Kingdom, and enrolled a total of 1077 participants, divided evenly between both arms. The comparator was the meningococcal conjugate vaccine MenACWY, chosen for its similar adverse event profile. Participants were aged 18 to 55 years old, and were excluded if any of the following were present: history of confirmed SARS-CoV-2, at higher risk for SARS-CoV-2 exposure (e.g., frontline healthcare worker) and those with new-onset symptoms consistent with COVID-19 (fever, cough, etc.). The median age was 35 years (interquartile range [IQR] 28 to 44 years) and 536 (49.8%) were female; 979 (90.9%) participants were Caucasian. The first co-primary endpoint was the safety of the ChAdOx1 nCoV-2 vaccine as measured by serious adverse events, and the second co-primary endpoint was the vaccine’s efficacy as measured by symptomatic, confirmed COVID-19 cases. Although adverse events were more common in the ChAdOx1 nCoV-2 group (e.g., 70% of participants reported fatigue versus 48% in the comparator arm), no serious adverse events were experienced in the former, and adverse reaction rates showed significant reductions with prophylactic paracetamol. Antibodies against SARS-CoV-2 spike protein reached maximal levels by day 28 (median 157 ELISA units, IQR 96 to 317; n=127) and remained high until day 56 (119 ELISA units, 70 to 203; n=43). Using the plaque reduction neutralization test, 35 participants in contact with SARS-CoV-2 (100%) achieved neutralizing titres (median titre 218, IQR 122 to 395); prophylactic paracetamol had no effect on immunogenicity of this vaccine. In summary, the novel ChAdOx1 nCoV-2 single-dose vaccine offered a promising safety and immunogenicity profile in preliminary investigations, meriting further investigation in older adults and with larger-scale phase 2 and 3 trials.

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

RELATED REPORTS

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

Effectiveness of second dose of COVID-19 vaccines over a 6 month period

Vaccinated individuals less likely to develop SARS-CoV-2 anti-nucleocapsid antibodies post-infection

Tags: covidSARS-CoV-2vaccine
Previous Post

Hydroxychloroquine and azithromycin do not improve clinical outcomes in mild-to-moderate Covid-19

Next Post

Effectiveness of the ready to reduce risk (3r) complex intervention for the primary prevention of cardiovascular disease

RelatedReports

Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Baricitinib reduces mortality risk in patients hospitalized with COVID-19

August 11, 2022
Medical vaccine exemptions increase after elimination of nonmedical exemptions
Infectious Disease

Effectiveness of second dose of COVID-19 vaccines over a 6 month period

July 26, 2022
Compliance-linked incentives increase infant immunizations rates in rural India
Infectious Disease

Vaccinated individuals less likely to develop SARS-CoV-2 anti-nucleocapsid antibodies post-infection

July 18, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
COVID-19 Classics

Inactivated whole-virion SARS-CoV-2 vaccine reduces rates of symptomatic COVID-19 infections [Classics Series]

August 3, 2022
Next Post

Effectiveness of the ready to reduce risk (3r) complex intervention for the primary prevention of cardiovascular disease

Racial, ethnic differences in outcomes of extremely preterm infants decreasing but persistent

Breastfeeding recommended as primary neonatal analgesic in low resource settings

#VisualAbstract: Myomectomy associated with better fibroid-related quality of life versus uterine-artery embolization

#VisualAbstract: Myomectomy associated with better fibroid-related quality of life versus uterine-artery embolization

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Provision of 1-year mortality data for patients hospitalized with heart failure does not influence clinical decision-making – The REVEAL-HF trial
  • Genetic risk for hemochromatosis associated with abnormal iron deposition localized to motor circuits of the brain
  • Graded sensorimotor retraining may improve chronic lower back pain compared to sham procedure: The RESOLVE randomized clinical trial
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.